
British pharmaceutical giant GlaxoSmithKline has been ordered to pay back £1.5 million to the Scottish Government because of its failure …

The FDA handed approval to Spark Therapeutics’ gene therapy for an inherited eye disorder, making it the first treatment of …

Vraylar (cariprazine), a drug developed as part of a partnership between Allergan and Gedeon Richter, has demonstrated strong results at …

Boehringer Ingelheim has moved early to secure an exclusive option on Autifony’s lead candidate for the treatment of schizophrenia, AUT00206, …

Following in the steps of authorities in the European Union, Australia and the United Kingdom, the FDA has pledged to …

Warning shots have been fired by both the General Medical Council (GMC) and the Labour Party about the recruitment issues …

Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million …

With access to rare disease treatments coming under increasing attention, both in the EU and the US, Pharmafile.com took the …

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …

Apotex, the world’s seventh largest generics manufacturer, has lost its Chairman and founder, after Barry Sherman and his wife, Honey, …

Boehringer Ingelheim is set to part ways with its Chief Financial Officer Simone Menne after 16 months due to fundamental …

There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …

Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration. …

Just 10 days away from Christmas, and big news is still flowing in the industry. Sanofi remains embroiled in scandal …